Glympse Bio, a biotechnology company advancing the way diseases are understood, tracked, and treated, announced that it has raised $46.7 million Series B financing. The proceeds from the financing will support continued development of Glympse’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases. The financing round was led…